The effect of a selective α2-adrenergic receptor antagonist (midaglizole) on the cyclic 3′,5′-adenosine monophosphate production in human mononuclear cells

Haruhito Sugiyama, Hidefumi Miyagawa, Chiharu Okada, Russell J. Hopp, Againdra K. Bewtra, Robert G. Townley

Research output: Contribution to journalArticle

Abstract

A selective α2-adrenergic antagonist, midaglizole, has been recently reported to have efficacy in patients with asthma. To understand the mechanisms, we investigated the effect of midaglizole on the cyclic 3′,5′-adenosine monophosphate (cAMP) production in human mononuclear cells (MNCs). MNCs were separated by a histopaque gradient from 10 normal subjects and 10 subjects with asthma. cAMP was measured by RIA kits. Midaglizole (10 μmol/L) significantly enhanced isoproterenol-induced cAMP production in both groups, although midaglizole (from 1 to 100 μmol/L) did not increase the cAMP production by itself. The percent increase in cAMP was more in subjects with asthma (183.8%) than in normal subjects (140.4%); however, the absolute increase was not different. Platelet-activating factor has been demonstrated to inhibit β-agonist-induced cAMP production in several mammalian tissues, including human MNCs. Midaglizole also prevented platelet-activating factor-induced desensitization of the cAMP response to isoproterenol in MNCs. These findings suggest that midaglizole may be a useful additional agent for the therapy of bronchial asthma through an enhancement of the cAMP production.

Original languageEnglish
Pages (from-to)722-729
Number of pages8
JournalJournal of Allergy and Clinical Immunology
Volume89
Issue number3
DOIs
StatePublished - 1992

Fingerprint

Adrenergic Antagonists
Adenosine Monophosphate
Asthma
Platelet Activating Factor
Isoproterenol
midaglizole

All Science Journal Classification (ASJC) codes

  • Immunology
  • Immunology and Allergy

Cite this

The effect of a selective α2-adrenergic receptor antagonist (midaglizole) on the cyclic 3′,5′-adenosine monophosphate production in human mononuclear cells. / Sugiyama, Haruhito; Miyagawa, Hidefumi; Okada, Chiharu; Hopp, Russell J.; Bewtra, Againdra K.; Townley, Robert G.

In: Journal of Allergy and Clinical Immunology, Vol. 89, No. 3, 1992, p. 722-729.

Research output: Contribution to journalArticle

@article{c78d6ee495804ed09658985b784ac4f8,
title = "The effect of a selective α2-adrenergic receptor antagonist (midaglizole) on the cyclic 3′,5′-adenosine monophosphate production in human mononuclear cells",
abstract = "A selective α2-adrenergic antagonist, midaglizole, has been recently reported to have efficacy in patients with asthma. To understand the mechanisms, we investigated the effect of midaglizole on the cyclic 3′,5′-adenosine monophosphate (cAMP) production in human mononuclear cells (MNCs). MNCs were separated by a histopaque gradient from 10 normal subjects and 10 subjects with asthma. cAMP was measured by RIA kits. Midaglizole (10 μmol/L) significantly enhanced isoproterenol-induced cAMP production in both groups, although midaglizole (from 1 to 100 μmol/L) did not increase the cAMP production by itself. The percent increase in cAMP was more in subjects with asthma (183.8{\%}) than in normal subjects (140.4{\%}); however, the absolute increase was not different. Platelet-activating factor has been demonstrated to inhibit β-agonist-induced cAMP production in several mammalian tissues, including human MNCs. Midaglizole also prevented platelet-activating factor-induced desensitization of the cAMP response to isoproterenol in MNCs. These findings suggest that midaglizole may be a useful additional agent for the therapy of bronchial asthma through an enhancement of the cAMP production.",
author = "Haruhito Sugiyama and Hidefumi Miyagawa and Chiharu Okada and Hopp, {Russell J.} and Bewtra, {Againdra K.} and Townley, {Robert G.}",
year = "1992",
doi = "10.1016/0091-6749(92)90380-K",
language = "English",
volume = "89",
pages = "722--729",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - The effect of a selective α2-adrenergic receptor antagonist (midaglizole) on the cyclic 3′,5′-adenosine monophosphate production in human mononuclear cells

AU - Sugiyama, Haruhito

AU - Miyagawa, Hidefumi

AU - Okada, Chiharu

AU - Hopp, Russell J.

AU - Bewtra, Againdra K.

AU - Townley, Robert G.

PY - 1992

Y1 - 1992

N2 - A selective α2-adrenergic antagonist, midaglizole, has been recently reported to have efficacy in patients with asthma. To understand the mechanisms, we investigated the effect of midaglizole on the cyclic 3′,5′-adenosine monophosphate (cAMP) production in human mononuclear cells (MNCs). MNCs were separated by a histopaque gradient from 10 normal subjects and 10 subjects with asthma. cAMP was measured by RIA kits. Midaglizole (10 μmol/L) significantly enhanced isoproterenol-induced cAMP production in both groups, although midaglizole (from 1 to 100 μmol/L) did not increase the cAMP production by itself. The percent increase in cAMP was more in subjects with asthma (183.8%) than in normal subjects (140.4%); however, the absolute increase was not different. Platelet-activating factor has been demonstrated to inhibit β-agonist-induced cAMP production in several mammalian tissues, including human MNCs. Midaglizole also prevented platelet-activating factor-induced desensitization of the cAMP response to isoproterenol in MNCs. These findings suggest that midaglizole may be a useful additional agent for the therapy of bronchial asthma through an enhancement of the cAMP production.

AB - A selective α2-adrenergic antagonist, midaglizole, has been recently reported to have efficacy in patients with asthma. To understand the mechanisms, we investigated the effect of midaglizole on the cyclic 3′,5′-adenosine monophosphate (cAMP) production in human mononuclear cells (MNCs). MNCs were separated by a histopaque gradient from 10 normal subjects and 10 subjects with asthma. cAMP was measured by RIA kits. Midaglizole (10 μmol/L) significantly enhanced isoproterenol-induced cAMP production in both groups, although midaglizole (from 1 to 100 μmol/L) did not increase the cAMP production by itself. The percent increase in cAMP was more in subjects with asthma (183.8%) than in normal subjects (140.4%); however, the absolute increase was not different. Platelet-activating factor has been demonstrated to inhibit β-agonist-induced cAMP production in several mammalian tissues, including human MNCs. Midaglizole also prevented platelet-activating factor-induced desensitization of the cAMP response to isoproterenol in MNCs. These findings suggest that midaglizole may be a useful additional agent for the therapy of bronchial asthma through an enhancement of the cAMP production.

UR - http://www.scopus.com/inward/record.url?scp=0026599982&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026599982&partnerID=8YFLogxK

U2 - 10.1016/0091-6749(92)90380-K

DO - 10.1016/0091-6749(92)90380-K

M3 - Article

C2 - 1347546

AN - SCOPUS:0026599982

VL - 89

SP - 722

EP - 729

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 3

ER -